Three medications are approved by the U.S. Food and Drug Administration specifically to treat alcohol use disorder, and several more are prescribed off-label with growing evidence behind them. Despite this, the vast majority of people who could benefit from these drugs never receive them. The medications work through different brain pathways, suit different treatment goals, and come with different side-effect profiles, so finding the right fit usually involves some conversation with a doctor rather than a one-size-fits-all prescription.
The Three FDA-Approved Options
The three medications with formal FDA approval for alcohol use disorder are naltrexone, acamprosate, and disulfiram. Each one targets a distinct piece of the puzzle, and understanding the differences matters because they are not interchangeable.
Naltrexone blocks opioid receptors in the brain, which blunts the pleasurable buzz alcohol normally delivers. A meta-analysis of human laboratory studies found that the drug both reduces alcohol’s rewarding effects and slightly amplifies its unpleasant ones, though the individual effects are small in magnitude.1PubMed Central. Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis In plain terms, drinking on naltrexone feels less satisfying, so over time you tend to drink less. It comes in a daily pill form (50 mg) and as a once-monthly injection called Vivitrol, which can help people who struggle to remember or choose to take a daily pill.2PubMed Central. Naltrexone long-acting formulation in the treatment of alcohol dependence
Acamprosate works on a completely different system. Chronic heavy drinking throws the brain’s excitatory and calming signals out of balance, and acamprosate helps restore equilibrium in the glutamate system, the brain’s main excitatory pathway.3PubMed Central. The clinical pharmacology of acamprosate It is best suited for people who have already stopped drinking and want to stay stopped, because it eases the restlessness, anxiety, and craving that linger for weeks or months after the last drink. It has an excellent safety profile and works well in a broad population of patients.4PubMed. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence The main practical drawback is that it must be taken three times a day, which can be a lot to manage.
Disulfiram, sold under the brand name Antabuse, takes a different approach entirely. It blocks the enzyme that breaks down a toxic byproduct of alcohol called acetaldehyde. If you drink while taking disulfiram, acetaldehyde builds up and you feel terrible: flushing, headache, nausea, and sometimes vomiting.5PubMed Central. Disulfiram: Mechanisms, Applications, and Challenges It is essentially a deterrent. Some people find the knowledge that drinking will make them physically sick to be a powerful motivator, but the drug only works as long as you keep taking it, and people who want to drink can simply skip the pill.
Off-Label Medications With Promising Evidence
Beyond the three FDA-approved drugs, several medications developed for other conditions have shown real promise for alcohol problems. Doctors can prescribe them “off-label,” meaning the drug is FDA-approved for something else but used based on clinical evidence.
Topiramate, originally an anti-seizure medication, has been studied in controlled trials for alcohol dependence. In one study, patients who received low-dose topiramate alongside standard treatment stayed abstinent for a median of ten weeks, compared to four weeks in the group that received no additional medication, and their relapse rate was lower as well.6PubMed Central. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study Side effects like tingling in the hands and feet, cognitive fogginess, and weight loss can be bothersome, but the weight loss is sometimes seen as a bonus by patients.
Gabapentin, another seizure medication, has attracted interest because it appears to help with several dimensions of alcohol use disorder at once: craving, sleep disruption, and the anxious or low mood that often follows quitting.7PubMed Central. Gabapentin for the treatment of alcohol use disorder A systematic review found clearer evidence for gabapentin’s effectiveness against alcohol craving and withdrawal symptoms compared with some other psychiatric conditions it is used for.8PubMed Central. Gabapentin Therapy in Psychiatric Disorders: A Systematic Review However, gabapentin itself carries some abuse potential, so prescribers need to weigh that risk.
Baclofen, a muscle relaxant, has attracted particular attention for people with liver cirrhosis, a group that desperately needs help but faces limited options because many medications are processed by the liver. In a randomized trial of patients with both alcohol dependence and liver cirrhosis, about 71% of those on baclofen achieved and maintained abstinence, compared with 29% on placebo, and no liver side effects were recorded.9The Lancet. Baclofen in the treatment of alcohol-dependent patients with liver cirrhosis: a randomised, double-blind, placebo-controlled trial A decade of follow-up research has continued to support both baclofen’s effectiveness and its safety in this population.10PubMed Central. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence
As-Needed Dosing and the Sinclair Method
One question people frequently have about naltrexone is whether you have to take it every day. The standard approach is daily dosing, but there is a well-studied alternative: taking naltrexone only before you plan to drink. This is sometimes called the Sinclair Method, named after researcher John David Sinclair, who proposed that naltrexone’s real power comes from a process called pharmacological extinction. When alcohol no longer delivers the expected reward because opioid receptors are blocked, the brain gradually unlearns the association between drinking and pleasure. But that unlearning only happens when you drink on the medication, not when you sit sober on the couch.11Alcohol and Alcoholism. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism
A clinical trial tested this targeted approach in 121 outpatients who were still actively drinking. After an initial 12-week period of daily naltrexone, participants switched to taking the medication only when they felt a craving. The results held: heavy drinking stayed reduced, and the study also showed that full detoxification before starting the medication was not required.12Journal of Clinical Psychopharmacology. Targeted Use of Naltrexone Without Prior Detoxification in the Treatment of Alcohol Dependence: A Factorial Double-Blind, Placebo-Controlled Trial Animal research has added a biological rationale: continuous delivery of opioid blockers can lead to tolerance and a compensatory increase in opioid receptor sensitivity, potentially undermining the drug’s benefit, whereas intermittent dosing avoids this problem.13PubMed. Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors
The as-needed approach appeals to people whose goal is to gradually cut down rather than quit cold turkey. It is not for everyone, and it requires honest self-awareness about when you are about to drink, but it is a legitimate, evidence-backed strategy.
Safety, Side Effects, and the Liver Question
One of the biggest fears people have about these medications is liver damage, which makes sense given that heavy drinking already takes a toll on the liver. The good news on naltrexone is more reassuring than many doctors realize. A pharmacovigilance analysis found that oral naltrexone was actually associated with lower odds of elevated liver enzymes compared to what you would expect, and injectable naltrexone showed even lower odds.14Clinical Gastroenterology and Hepatology. Gastrointestinal and Liver Adverse Effects of Alcohol Use Disorder Medications: A Pharmacovigilance Analysis Studies specifically examining naltrexone in patients with cirrhosis found no cases of drug-induced liver injury using formal scoring systems, and liver enzyme levels actually improved after starting the drug, likely because patients were drinking less.15PubMed Central. Safety of naltrexone in patients with cirrhosis16PubMed Central. Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease
Disulfiram tells a different story. The same pharmacovigilance analysis flagged it with dramatically higher odds of acute liver failure and drug-induced liver injury, which is why doctors monitor liver function closely in anyone prescribed it.14Clinical Gastroenterology and Hepatology. Gastrointestinal and Liver Adverse Effects of Alcohol Use Disorder Medications: A Pharmacovigilance Analysis Acamprosate, by contrast, is processed by the kidneys rather than the liver, so it is generally safe for people with liver disease. Its most common gastrointestinal side effect is diarrhea rather than nausea.
Each medication has its own profile of everyday side effects worth knowing about:
- Naltrexone (oral): Nausea is the most common complaint, especially in the first week or two. Taking it with food or at bedtime often helps.
- Naltrexone (injectable): Injection-site reactions and nausea, though the injectable form appears to cause fewer gastrointestinal side effects overall than the pill.
- Acamprosate: Diarrhea and gas are the main nuisances. Nausea is actually less common than with many alternatives.
- Disulfiram: Without alcohol, side effects are mild (drowsiness, metallic taste). With alcohol, the reaction can be severe enough to require emergency medical attention.
One critical safety note: naltrexone blocks opioid receptors, which means it also blocks the effect of opioid painkillers. Anyone taking naltrexone needs to carry an alert card or wear a medical ID, because in a medical emergency, standard opioid pain relief will not work. This is not a reason to avoid the drug, but it is something emergency physicians and dentists need to know about.
Genetics and Who Responds Best
Not everyone responds equally to these medications, and researchers have been working to figure out why. The most studied genetic factor involves a variation in the gene for the brain’s main opioid receptor, called OPRM1. A meta-analysis found that people carrying a particular version of this gene (the G allele of the A118G variant) who took naltrexone had roughly twice the odds of avoiding relapse compared to those with the more common version.17PubMed. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis
The picture is getting more complex as researchers look beyond a single gene. A clinical trial found that naltrexone’s effectiveness also depended on variations in dopamine-related genes. The strongest responses showed up in people who carried specific combinations of both opioid and dopamine gene variants, with effect sizes reaching the moderate-to-large range.18PubMed Central. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial This kind of pharmacogenomic research is not yet part of routine clinical practice, but it signals a future where your doctor could run a genetic test to guide the choice of medication.
Withdrawal Is a Separate Medical Problem
People sometimes confuse medications for alcohol withdrawal with medications for long-term recovery, and the two are very different. Alcohol withdrawal can be life-threatening: it can cause seizures, dangerous spikes in heart rate and blood pressure, and a condition called delirium tremens. The medications used to manage withdrawal, primarily benzodiazepines, are short-term tools for keeping a person safe during the acute phase.19PubMed Central. Benzodiazepine maintenance for alcohol dependence: A case series Anticonvulsant medications are also increasingly used during this phase.20PubMed Central. Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders
Once withdrawal is over, benzodiazepines have no role in ongoing treatment. They are themselves habit-forming and can be dangerous when mixed with alcohol. The medications discussed in this article, naltrexone, acamprosate, disulfiram, and the off-label options, are the ones meant for the longer road of staying on track. If you are a heavy daily drinker and want to stop, talk to a doctor before quitting abruptly. Medical supervision during withdrawal is not optional for people who drink large amounts every day.
Medication Plus Therapy
A natural follow-up question is whether medication alone is enough. The research suggests that combining medication with structured counseling, particularly cognitive-behavioral therapy, usually works better than either one by itself, though the advantage is not as dramatic as you might expect. A systematic review found that about half of the randomized trials looking at this question showed a measurable added benefit from combining therapy with medication, compared with therapy alone.21PubMed Central. The Added Value of Pharmacotherapy to Cognitive Behavior Therapy And Vice Versa in the Treatment of Alcohol Use Disorders: A Systematic Review A separate meta-analysis found that combined treatment outperformed usual care, but that cognitive-behavioral therapy specifically did not clearly outperform other forms of therapy when both were paired with medication.22JAMA Network Open. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis
The practical takeaway is that medication and counseling complement each other, but if access to therapy is a barrier, medication alone still helps. Waiting until you can get into a therapy program to start medication is a common mistake. Starting the medication is often the step that gives you enough traction to engage with counseling when it does become available.
Does the Goal Have to Be Quitting Entirely?
Historically, alcohol treatment assumed abstinence was the only acceptable outcome. That has been shifting. A systematic review and meta-analysis comparing abstinence-oriented and controlled-drinking interventions found no significant difference in the proportion of participants who got their drinking to recommended levels.23PubMed. Controlled drinking-non-abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-analysis and meta-regression Both approaches also performed similarly on social functioning and overall reductions in drinking. This matters because some people who are unwilling to commit to total abstinence will accept a harm-reduction goal, and getting them into treatment is better than not treating them at all.
Naltrexone fits well with a reduction goal because it works even while you are still drinking. Acamprosate, on the other hand, is designed for people who have already stopped and want to maintain abstinence. Disulfiram is inherently an abstinence tool, since its entire mechanism depends on making you sick if you drink. Matching the medication to your personal goal is an important part of getting started.
Why So Few People Get These Medications
Given that effective medications exist, the natural question is why they remain so underused. Research into how primary care doctors make prescribing decisions reveals several entrenched barriers. Many physicians lack knowledge and hands-on experience with these drugs, or hold a belief that medication cannot replace specialty addiction treatment and should not be started outside a formal program.24PubMed Central. Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics Alcohol-related stigma also plays a role: some doctors remain uncomfortable discussing alcohol use, and some patients avoid raising it.25The Annals of Family Medicine. Prescribing Medications for Alcohol Use Disorder: A Qualitative Study of Primary Care Physician Decision Making
Insurance coverage adds another layer of difficulty. Qualitative research on insurance barriers to substance use treatment found that out-of-pocket costs can be prohibitive, with some medications costing hundreds of dollars per month for patients whose plans do not cover them adequately.26PubMed Central. Insurance barriers to substance use disorder treatment after passage of mental health and addiction parity laws and the affordable care act: A qualitative analysis Generic oral naltrexone and acamprosate are relatively inexpensive, but the injectable form of naltrexone can cost well over a thousand dollars a month without insurance. If your doctor has not brought up medication, it is worth asking. Primary care is an appropriate setting for prescribing these drugs, and you do not necessarily need a referral to a specialist.
What Is on the Horizon
Two emerging therapies are getting significant attention, though neither is ready for routine use yet. The first is semaglutide, better known as the active ingredient in the weight-loss drugs Ozempic and Wegovy. A randomized clinical trial in adults with alcohol use disorder found that low-dose semaglutide reduced the amount of alcohol consumed in a lab setting, cut drinks per drinking day, and lowered weekly craving scores, all with medium-to-large effect sizes.27PubMed Central. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial It did not reduce the total number of days participants drank, suggesting it may work more by dampening the intensity of drinking rather than preventing it altogether. Larger trials are underway.
The second is psilocybin, the psychoactive compound in certain mushrooms, given in a controlled therapeutic setting with psychological support. In a randomized trial of 95 patients, those who received psilocybin-assisted therapy had a mean of about 10% heavy drinking days during follow-up, compared to about 24% in the control group.28PubMed Central. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder Psilocybin is not a take-home pill; the therapeutic model involves one or two dosing sessions under professional supervision with preparation and integration therapy before and after. It remains a Schedule I substance in the United States, so access outside of clinical trials is currently not legal.
Neither semaglutide nor psilocybin is likely to replace existing medications anytime soon, but they represent genuinely novel approaches that work through mechanisms unrelated to any current treatment. For people who have tried the available options without success, the pipeline of future therapies is more active than it has been in decades.